The NUB reimbursement pathway has been effective in bringing high-cost innovative medical technologies to the German market, but there are challenges. In MedTech Strategist, we assess the funding of medtech through NUBs and outlines the strengths and weaknesses of the NUB pathway.
Pharmaceuticals and Biotechnology Litigation
In this Jan-Mar 2023 issue of Corporate Disputes e-magazine, Sean Sheridan, along with other industry professionals, discusses significant developments shaping...